Alphyn Biologics Presents Pediatric Data from Atopic Dermatitis Trial ... - PR Newswire
| 4142 Stock | TWD 23.30 0.45 1.89% |
Slightly above 62% of Adimmune Corp's investor base is looking to short. The analysis of current outlook of investing in Adimmune Corp suggests that many traders are alarmed regarding Adimmune Corp's prospects. Adimmune Corp's investing sentiment can be driven by a variety of factors including economic data, Adimmune Corp's earnings reports, geopolitical events, and overall market trends.
Adimmune Corp stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Adimmune daily returns and investor perception about the current price of Adimmune Corp as well as its diversification or hedging effects on your existing portfolios.
Adimmune |
Alphyn Biologics Presents Pediatric Data from Atopic Dermatitis Trial ... PR Newswire
Read at news.google.com
 |
Adimmune Corp Fundamental Analysis
We analyze Adimmune Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adimmune Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adimmune Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Adimmune Corp is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Adimmune Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Adimmune Corp stock to make a market-neutral strategy. Peer analysis of Adimmune Corp could also be used in its relative valuation, which is a method of valuing Adimmune Corp by comparing valuation metrics with similar companies.
Peers
Adimmune Corp Related Equities
| 6547 | Medigen Vaccine | 0.71 | ||||
| 4119 | SCI Pharmtech | 0.35 | ||||
| 1789 | ScinoPharm Taiwan | 0.65 | ||||
| 4133 | Abnova Taiwan | 1.32 | ||||
| 1762 | Chunghwa Chemical | 1.55 |
Additional Tools for Adimmune Stock Analysis
When running Adimmune Corp's price analysis, check to measure Adimmune Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adimmune Corp is operating at the current time. Most of Adimmune Corp's value examination focuses on studying past and present price action to predict the probability of Adimmune Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adimmune Corp's price. Additionally, you may evaluate how the addition of Adimmune Corp to your portfolios can decrease your overall portfolio volatility.